Independent Market Access and Reimbursement Risk Assessment.

Built by former payers, HTA reviewers, and Industry Experts. 

Jaypirca / Pirtobrutinib for Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Without a Known 17p Deletion

As of October 2026, MARA’s assessment finds Jaypirca / Pirtobrutinib’s reimbursement risk concentrated in comparator selection, with evidence quality and robustness a strength; the current MARA Rating and full rationale are available in the report.

The assessment also weighs patient population and subgroups: how closely the trial population matches the patients who would receive the drug in practice; payers often restrict funding to the groups where the evidence is strongest. The strength recorded in evidence quality and robustness carries weight because that domain asks how solid the underlying evidence is on its own terms — trial design, size and endpoints — before any question of price is reached.

Oncology

This rating sits within MARA’s Oncology coverage, alongside 168 other independently assessed treatments in the same area.

What payers will ask

Is the clinical benefit the kind payers reward? — Clinical effectiveness

BRUIN CLL-313 demonstrated superiority over bendamustine–rituximab for IRC-assessed PFS with a HR of 0.20 (95% CI 0.11–0.37; p<0.0001). However, the comparator is outdated, and there is no direct evidence against newer targeted therapies like acalabrutinib or zanubrutinib.

Does the economic case hold at the expected price? — Cost effectiveness

No economic model or ICER for first-line pirtobrutinib was identified in the public evidence.

Is there quality-of-life evidence payers weigh? — Quality of life

No pirtobrutinib-specific HRQoL data were reported, despite planned collection using EORTC QLQ-C30 and EQ-5D-5L in the trial SAP.

Does the safety profile hold up for payers? — Safety and Adverse Effects

Pirtobrutinib showed fewer grade ≥3 events and treatment discontinuations than bendamustine–rituximab. However, long-term safety data are limited, and there is no direct comparison with newer BTK inhibitors.

Was the drug compared against what payers expect? — Comparator Selection

Bendamustine–rituximab is no longer the most relevant comparator in many settings. The trial does not establish superiority over current preferred targeted therapies.

Is the population defined the way payers need it? — Patient Population and Subgroups

The trial population was globally recruited but had low Black representation and excluded frailer patients. Subgroup analyses were limited.

Does the drug fit how care is delivered and paid for? — Care Pathway Integration

Pirtobrutinib is an oral therapy with familiar monitoring requirements, but continuous therapy imposes an indefinite follow-up burden.

Are the wider system costs understood? — Resource Use and Cost Implications

No budget-impact or resource-use data were presented.

Would the evidence survive payer scrutiny? — Evidence Quality and Robustness

The trial was a properly randomized phase III study with robust PFS results. However, it was open-label, and some subgroup and PRO data were missing.

How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts

High uncertainty due to immature OS, crossover, and lack of modern comparator data. Economic uncertainty is greater due to the absence of a first-line model.

Be alerted when this rating changes:

Sample two-page MARA Rating report for the fictional drug Samplinib: page one with the rating, its key numbers and the past decisions on drugs in the same rating band; page two with the ten graded payer-side domains and the reasoning behind each
Every MARA rating is delivered as a two-page reasoned report (sample, fictional product) — see it in full
Full Legal Disclaimer and Usage Terms

The MARA Rating® is an independent opinion of a drug’s market access pharma risk profile and is provided for informational purposes only—not as investment, medical, legal or any other type of advice. See our full disclaimer here.